ONCOGENIC ALTERATIONS IN NSCLC

 

Select oncogenic alterations can drive non-small cell lung cancer development1-10

 

Graph showing the percentage of the NSCLC population affected by different oncogenic alterations Graph showing the percentage of the NSCLC population affected by different oncogenic alterations

 

aEGFR mutations vary by ethnicity. EGFR mutations may be found in ~31% of Asian patients and 7% to 8% of other ethnic populations. EGFR alterations associated with resistance were excluded. Additional alterations exist within the EGFR gene that may individually account for <1% of NSCLC cases and collectively account for ~10%.1,11
bALK alterations associated with resistance were excluded.1
cBRAF alterations associated with resistance were excluded.1
dMET alterations associated with resistance were excluded. Additional alterations can occur within the MET gene that may account for <1% of NSCLC cases.1
MET amplification may account for ~1%-6% of NSCLC cases.12-14

 

It is important to know your patients’ oncogenic alteration status through genomic profiling.15,16

 

 

MET dysregulation >

NSCLC, non-small cell lung cancer.

 

 

References

1. Chakravarty D, Gao J, Phillips S, et al. JCO Precis Oncol. 2017. doi:10.1200/PO.17.00011. Accessed October 16, 2019.
2. Shigematsu H, Lin L, Takahashi T, et al. J Natl Cancer Inst. 2005;97(5):339-346.
3. Li A, Chitale D, Riely GJ, et al. J Mol Diagn. 2008;19(3):242-248.
4. Ross JS, Ali SM, Fasan O, et al. Oncologist. 2017;22(12):1444-1450.
5. Gainor JF, Varghese AM, Ou SH, et al. Clin Cancer Res. 2013;19(15):4273-4281.
6. Awad MM, Oxnard GR, Jackman DM, et al. J Clin Oncol. 2016;34(7):721-730.
7. Mazières J, Peters S, Lepage B, et al. J Clin Oncol. 2013;31(16):1997-2004.
8. Lin Q, Zhang H, Ding H, et al. J Transl Med. 2019;17:1-10.
9. Tissot C, Couraud S, Tanguy R, Bringuier P-P, Girard N, Souquet P-J. Lung Cancer. 2016;91:23-28.
10. Bergethon K, Shaw AT, Ou SH, et al. J Clin Oncol. 2012;30(8):863-870.
11. Sekine I, Yamamoto N, Nishio K, Saijo N. Br J Cancer. 2008;99(11):1757-1762.
12. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Cancer Sci. 2008;99(11):2280-2285.
13. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. J Thorac Oncol. 2008;4:5-11.
14. Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A. Virchows Arch. 2017;1-7.
15. Awad MM, Leonard GC, Kravets S, et al. Lung Cancer. 2019;133:96-102.
16. Leighl NB, Rekhtman N, Biermann WA, et al. J Clin Oncol. 2014;32(32):3673-3679.


 

This is a global website and is intended for health care professionals. The information on this site is intended for educational purposes only and is not country-specific.

 

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2020 Novartis AG. All rights reserved.

10/19     G-CAP-1220183